10 Facts About Genentech

Genentech, Inc, is an American biotechnology corporation which became a subsidiary of Roche in 2009.

In March 2009 Roche acquired Genentech by buying shares it didn't already control for approximately $46.

In December 2006, Genentech sold its Porrino, Spain, facility to Lonza and acquired an exclusive right to purchase Lonza's mammalian cell culture manufacturing facility under construction in Singapore.

In June 2007, Genentech began the construction and development of an E coli manufacturing facility, in Singapore, for the worldwide production of Lucentis bulk drug substance.

Genentech is a donor to the Center for Health Care Strategies, a non-governmental organization that lobbies the United States Government on issues related to Medicaid.

Related searches

Genentech Inc Political Action Committee is a US Federal Political Action Committee, created to "aggregate contributions from members or employees and their families to donate to candidates for federal office".

In November 1999, Genentech agreed to pay the University of California, San Francisco $200 million to settle a nine-year-old patent dispute.

Genentech claimed that they developed Protropin, independently of UCSF.

Protropin, a drug used to treat dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to its position as an industry leader.

In 2009, The New York Times reported that Genentech's talking points on health care reform appeared verbatim in the official statements of several Members of Congress during the national health care reform debate.